GATA6 in pancreatic cancer initiation and progression  

作　　者：Muyuan Ma Jianhong An Tingting Jiang Keping Xie 

机构地区：[1]Center for Pancreatic Cancer Research,The South China University of Technology School of Medicine,Guangzhou,Guangdong 510006,China

出　　处：《Genes & Diseases》2025年第2期171-180,共10页基因与疾病(英文)

基　　金：supported by the Guangzhou Ruiqian Biotech Company (No.20230330 to T.J.);National Natural Science Foundation of China (No.82072632);Guangzhou Municipality Bureau of Science and Technology (China) (No.202102010033 to K.X.);the Natural Science Foundation of Guangdong Province,China (No.2022A1515012585 to K.X.).

摘　　要：t Pancreatic ductal adenocarcinoma(PDA)is a lethal malignancy characterized by insidious onset and lack of effective therapy.The molecular pathogenesis of PDA remains to be understood fully.Transcriptional factor GATA6 is an important transcriptional regulator in normal pancreas development,particularly in the initial specification and differentiation of the pancreas.Recent studies have linked pancreatic malignancy closely to GATA6.Increased levels of GATA6 expression enhance pancreatic cancer cell growth.GATA6 emerges as a line-age-specific oncogenic factor in PDA,augmenting the oncogenic phenotypes of PDA cells upon its overexpression.However,elevated GATA6 levels are correlated with well-differentiated tu-mors and a more favorable patient prognosis.Experimental evidence in genetic mouse models has revealed a tumor-suppressive role for GATA6.The circumstantial roles of GATA6 in pancre-atic tumorigenesis remain to be defined.This review aims to elucidate recent advances in com-prehending GATA6,emphasizing its crucial roles in both pancreas physiology and pathology.Special attention will be given to its involvement in PDA pathogenesis,exploring its potential as a novel biomarker and a promising therapeutic target for PDA.

关 键 词：GATA6 INFLAMMATION Molecular diagnosis PANCREAS Targeted therapy TUMORIGENESIS 

分 类 号：R73[医药卫生—肿瘤]